The biotech company, which was founded in St. Louis, relocates as two of its cofounders are joining the faculty at the University of Maryland. KaloCyte is developing a synthetic blood product.

A biotechnology company developing a synthetic blood product that could be used in trauma settings is joining the community at Baltimore’s University of Maryland BioPark.

KaloCyte, which is relocating from St. Louis, will become an affiliate member of the BioPark, the company said in a news release on Monday.

The company is developing a red blood cell substitute, called ErythroMer, which is designed to capture and release oxygen like a normal red blood cell. The company said it could be used in both civilian and military settings.

Read the full story at Technical.ly Baltimore.